Home| Journals | Statistics Online Expert | About Us | Contact Us

    About this Journal  | Table of Contents

[Abstract] [PDF] [HTML] [Linked References]

International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN: 2249-8109

Volume 12, Issue 2, September 2014 pp 295-298

Research Article

Clinico-pathological study on role of frozen section in ovarian lesions at a tertiary care hospital in south India

Nisha J Marla1, Athulya C2, Hilda Fernandes3, Jayaprakash C S4

1Associate Professor, 2Resident, 3,4Profesor, Department of Pathology, Father Muller Medical College, Mangalore, Karnataka, INDIA.



Background: Ovarian neoplasms are an important cause of morbidity and mortality in women. Frozen section (FS) is an integral component in the assessment of ovarian neoplasms at laparoscopy or laparotomy. This study was undertaken to study and correlate FS with permanent histopathological sections in ovarian lesions. Materials and Methods: Intra-operative FS performed for ovarian lesion was analyzed prospectively and retrospectively in 45 patients who underwent surgery at our institution from January 2009 to July 2013.This was compared with the final histopathologic diagnosis on permanent paraffin sections. Results: Among 45 cases of ovarian lesions, the final histopathological diagnosis showed 31 benign tumors, 5 borderline tumors and 9 malignant tumors. The FS diagnosis correlated with the final histopathology in 43 cases (95.5%) and was discordant in 2 cases (4.4%). The overall sensitivity, specificity, positive predictive value and negative predictive value of FS was 97.2%, 88.8%, 97.2% and 88.8% respectively. The sensitivity of FS diagnosis for benign, borderline and malignant lesions was 96.7%, 100% and 88.8%; respectively and the specificities were 92.8%, 100% and 97.2% respectively. Conclusion: Intraoperative FS has high accuracy in the diagnosis of suspected ovarian neoplasms. It is a valuable tool to guide the surgical management of these patients and should be routinely used in all major oncology centres.